Optimal molecular-targeted therapies as first-line treatment for RAS wild-type, right-sided metastatic colorectal cancer from the Analysis and Research in Cancers of the Digestive System (ARCAD) database

被引:0
|
作者
Yamazaki, Kentaro
Takeda, Yuriko
Misumi, Toshihiro
Suzuki, Motoko
Wakabayashi, Masashi
Bando, Hideaki
Oki, Eiji
Douillard, Jean-Yves
Punt, Cornelis J. A.
Van Cutsem, Eric
Bokemeyer, Carsten
Venook, Alan P.
Maehara, Yoshihiko
Heinemann, Volker
Cremolini, Chiara
Nakayama, Goro
Andre, Thierry
Shi, Qian
De Gramont, Aimery
Yoshino, Takayuki
机构
[1] Shizuoka Canc Ctr, Div Gastrointestinal Oncol, Shizuoka, Japan
[2] Natl Canc Ctr Hosp East, Dept Data Sci, Kashiwa, Chiba, Japan
[3] Natl Canc Ctr Hosp East, Dept Gastroenterol & Gastrointestinal Oncol, Kashiwa, Chiba, Japan
[4] Kyushu Univ, Grad Sch Med Sci, Dept Surg & Sci, Fukuoka, Japan
[5] Univ Nantes, Med Sch Nantes, Nantes, France
[6] Univ Med Ctr Utrecht, Utrecht, Netherlands
[7] Univ Hosp Gasthuisberg Leuven, Dept Gastroenterol Digest Oncol, Leuven, Belgium
[8] Katholieke Univ Leuven, Leuven, Belgium
[9] Univ Med Ctr Hamburg Eppendorf, Dept Oncol Hematol, Hamburg, Germany
[10] Univ Med Ctr Hamburg Eppendorf, Bone Marrow Transplantat Sect Pneumol, Hamburg, Germany
[11] Univ Calif San Francisco, Dept Med, San Francisco, CA USA
[12] Kyushu Cent Hosp, Mutual Aid Assoc Publ Sch, Fukuoka, Japan
[13] Ludwig Maximilians Univ Munchen, Univ Hosp, Dept Med 3, Munich, Germany
[14] Univ Hosp Pisa, Dept Oncol, Pisa, Italy
[15] Nagoya Univ, Dept Surg Gastroenterol, Grad Sch Med, Nagoya, Aichi, Japan
[16] Hop St Antoine, Paris, France
[17] Mayo Clin, Dept Quantitat Sci Res, Rochester, MN USA
[18] Franco British Hosp, Dept Med Oncol, Levallois Perret, France
关键词
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
3588
引用
收藏
页数:1
相关论文
共 50 条
  • [41] Survival benefit of metastasectomy in first-line cetuximab therapy in patients with RAS wild-type metastatic colorectal cancer: a nationwide registry
    Chen, Chou-Chen
    Chang, Shih-Ching
    Chang, Yu-Yao
    Lin, Bo-Wen
    Chen, Hong-Hwa
    Hsieh, Yao-Yu
    Hsu, Hung-Chih
    Hsieh, Meng-Che
    Ke, Tao-Wei
    Kuan, Feng-Che
    Wu, Chih-Chien
    Lu, Wei-Chen
    Su, Yu-Li
    Liang, Yi-Hsin
    Chen, Joe-Bin
    Huang, Hsuan-Yuan
    Tsai, Hsiang-Lin
    Wang, Jaw-Yuan
    AMERICAN JOURNAL OF CANCER RESEARCH, 2023, 13 (12):
  • [42] Epidermal growth factor inhibitors in first-line for metastatic colorectal cancer with ras wild-type: a perspective based on pharmacological costs
    Giuliani, Jacopo
    Bonetti, Andrea
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2017, 17 (03) : 243 - 248
  • [43] A SYSTEMATIC LITERATURE REVIEW TO IDENTIFY TRIALS IN FIRST-LINE RAS WILD-TYPE (WT) METASTATIC COLORECTAL CANCER (MCRC) PATIENTS
    Jarrett, J.
    Weijers, L.
    Hnoosh, A.
    Harty, G.
    von Hohnhorst, P.
    VALUE IN HEALTH, 2014, 17 (07) : A617 - A617
  • [44] Quality of life analysis in patients with RAS wild-type metastatic colorectal cancer treated with first-line FOLFIRI plus cetuximab in the CRYSTAL study
    Yamaguchi, K.
    Ando, M.
    Ooki, A.
    Beier, F.
    Guenther, S.
    Von Hohnhorst, P.
    Van Cutsem, E.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S370 - S371
  • [45] Tumor sidedness and efficacy of first-line therapy in patients with RAS/BRAF wild-type metastatic colorectal cancer: A network meta-analysis
    Wu, Chih-Chien
    Wang, Jui-Ho
    Lin, Pei-Chin
    Liang, Chun-An
    Huang, Ching-Ying
    Lien, Han-Chu
    Chen, Chung-Yu
    Chou, Kang-Ju
    Su, Yi-Chia
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2020, 145
  • [46] Evolution of RAS Mutations in Cell-Free DNA of Patients with Tissue RAS Wild-Type Metastatic Colorectal Cancer Receiving First-Line Treatment: The PERSEIDA Study
    Valladares-Ayerbes, Manuel
    Garcia-Alfonso, Pilar
    Luengo, Jorge Munoz
    Caceres, Paola Patricia Pimentel
    Trujillo, Oscar Alfredo Castillo
    Vidal-Tocino, Rosario
    Llanos, Marta
    Ayala, Beatriz Llorente
    Miron, Maria Luisa Limon
    Salud, Antonieta
    Nogueras, Luis Cirera
    Garcia-Carbonero, Rocio
    Safont, Maria Jose
    Ferrer, Esther Falco
    Aparicio, Jorge
    Conesa, Maria Angeles Vicente
    Guillen-Ponce, Carmen
    Garcia-Teijido, Paula
    Magan, Maria Begona Medina
    Busquier, Isabel
    Salgado, Mercedes
    Vila, Ariadna Lloansi
    CANCERS, 2022, 14 (24)
  • [47] Overall survival with cetuximab every-2-weeks versus standard once-weekly administration schedule for first-line treatment of RAS wild-type metastatic colorectal cancer in patients with left- and right-sided primary tumour location
    Kasper, Stefan
    Foch, Caroline
    Esser, Regina
    Zhang, Aimar
    Cheng, Ann-Lii
    Rouyer, Magali
    Brodowicz, Thomas
    Zielinski, Christoph
    EUROPEAN JOURNAL OF CANCER, 2023, 180 : 85 - 88
  • [48] BRAFV600E Mutation in First-Line Metastatic Colorectal Cancer: An Analysis of Individual Patient Data From the ARCAD Database
    Cohen, Romain
    Liu, Heshan
    Fiskum, Jack
    Adams, Richard
    Chibaudel, Benoist
    Maughan, Timothy S.
    Van Cutsem, Eric
    Venook, Alan
    Douillard, Jean-Yves
    Heinemann, Volker
    Punt, Cornelis Ja
    Falcone, Alfredo
    Bokemeyer, Carsten
    Kaplan, Richard
    Lenz, Heinz-Josef
    Koopman, Miriam
    Yoshino, Takayuki
    Zalcberg, John
    Grothey, Alex
    de Gramont, Aimery
    Shi, Qian
    Andre, Thierry
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2021, 113 (10): : 1386 - 1395
  • [49] First-line panitumumab plus capecitabine for the treatment of older patients with wild-type RAS metastatic colorectal cancer. The phase II, PANEL study
    Mendez Mendez, Jose Carlos
    Salgado Fernandez, Mercedes
    de la Camara Gomez, Juan
    Pellon Augusto, Mari Luz
    Covela Rua, Marta
    Quintero Aldana, Guillermo
    Fernandez Montes, Ana
    Reboredo Lopez, Margarida
    Valladares Ayerbes, Manuel
    Jorge Fernandez, Monica
    Gonzalez Villarroel, Paula
    Romero Reinoso, Carlos
    Ramos Vazquez, Manuel
    JOURNAL OF GERIATRIC ONCOLOGY, 2020, 11 (08) : 1263 - 1267
  • [50] Amphiregulin can predict treatment resistance to palliative first-line cetuximab plus FOLFIRI chemotherapy in patients with RAS wild-type metastatic colorectal cancer
    Kim, Sang-A
    Park, Hyejoo
    Kim, Kui-Jin
    Kim, Ji-Won
    Sung, Ji Hea
    Nam, Milang
    Lee, Ju Hyun
    Jung, Eun Hee
    Suh, Koung Jin
    Lee, Ji Yun
    Kim, Se Hyun
    Lee, Jeong-Ok
    Kim, Jin Won
    Kim, Yu Jung
    Kim, Jee Hyun
    Bang, Soo-Mee
    Lee, Jong Seok
    Lee, Keun-Wook
    SCIENTIFIC REPORTS, 2021, 11 (01)